Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease

MJ Volles, PT Lansbury - Biochemistry, 2003 - ACS Publications
MJ Volles, PT Lansbury
Biochemistry, 2003ACS Publications
Parkinson's disease (PD) is linked to mutations in the protein α-synuclein, which can exist in
vitro in several aggregation states, including a natively unfolded monomer, a β-sheet rich
oligomer, or protofibril, and a stable amyloid fibril. This work reviews the current literature
that is relevant to two linked questions: which of these species is pathogenic, and what is the
mechanism of neurotoxicity? The amyloid fibril, fibrillar aggregates, Lewy bodies, and the α-
synuclein monomer, which is normally expressed at high levels, are all unlikely to be …
Parkinson's disease (PD) is linked to mutations in the protein α-synuclein, which can exist in vitro in several aggregation states, including a natively unfolded monomer, a β-sheet rich oligomer, or protofibril, and a stable amyloid fibril. This work reviews the current literature that is relevant to two linked questions:  which of these species is pathogenic, and what is the mechanism of neurotoxicity? The amyloid fibril, fibrillar aggregates, Lewy bodies, and the α-synuclein monomer, which is normally expressed at high levels, are all unlikely to be pathogenic, for reasons discussed here. We therefore favor a toxic protofibril scenario, and propose that the pathogenic species is transiently populated during the process of fibrillization. Toxicity may arise from pore-like protofibrils that cause membrane permeabilization. An approach to testing this hypothesis is discussed.
ACS Publications